CTOs on the Move

Dianthus Therapeutics

www.dianthustx.com

 
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dianthustx.com
  • 203 Crescent Street. Building 4 Suite 205
    Waltham, MA USA 02453
  • Phone: 252.227.7013

Executives

Name Title Contact Details

Similar Companies

Agrinos

Agrinos is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint.

Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

Immunovant

Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.

Genome International Corporation

Genome International Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Helm Pharmaceuticals

Helm Pharmaceuticals is a Chappaqua, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.